Efficacy of Eldecalcitol (ED-71) in Colorectal Cancer

Eldecalcitol (ED-71) 在结直肠癌中的功效

• 批准号: 8739520
• 负责人: Michael Pawlita
• 金额: $ 30.37万
• 依托单位: RESEARCH INST OF FOX CHASE CAN CTR
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-18 至 2014-09-17
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8739520
• 关键词: Age; Animals; Apoptosis; Biological Markers; Blood Chemical Analysis; Blood specimen; Body Weight; Breeding; Carbon Dioxide; Cell Proliferation; Chemopreventive Agent; Cholecalciferol; Colon Carcinoma; Colonic Neoplasms; Colonic Polyps; Colorectal Cancer; Contractor; Contracts; Control Groups; Diet; Dose; Effectiveness; Euthanasia; Female; Frequencies; Gene Expression Profile; Genetic; Immunohistochemistry; Incidence; Intestinal Neoplasms; Intestines; Liver; Mediating; Messenger RNA; Methods; MicroRNAs; Molecular Target; Mus; Organ; Pre-Clinical Model; Reverse Transcriptase Polymerase Chain Reaction; Serum; Serum Calcium Level; Signal Transduction; Signaling Molecule; Small Intestinal Neoplasm; Small Intestinal Polyp; Staging; Symptoms; Testing; Tissues; Toxic effect; Tumor Suppression; Tumor Tissue; Western Blotting; base; cancer prevention; colorectal cancer prevention; feeding; in vivo; male; mouse model; prevent; research study; response; tumor

The overall objective is to develop Eldecalcitol (ED-71) for colorectal cancer prevention in a preclinical model. Specifically, the Contractor shall obtain required quantities of ED-71, establish the optimal dose and/or non-calcemic dose, perform in depth assessment of ED-7-mediated colon cancer prevention in APC-min mice, in addition to, identifying ED-71 specific molecular target(s) in preventing tumor frequency, incidence, multiplicity, etc. in APC-min mice.

总体目标是开发 Eldecalcitol (ED-71)，用于临床前模型中预防结直肠癌。具体而言，承包商应获得所需数量的 ED-71，确定最佳剂量和/或非钙血剂量，对 APC-min 小鼠中 ED-7 介导的结肠癌预防进行深入评估，此外，确定 ED-71 在预防 APC-min 小鼠中肿瘤频率、发生率、多重性等方面的特异性分子靶点。